Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced that Merck KGaA (ETR: MRK) has adopted its Bio-AI clinical prediction platform as part of the German major’s drug development pipeline. This means that selected preclinical small molecule candidates will now be tested through the Quris AI platform prior to entering clinical testing.
Background of the Partnership
Merck and Quris AI first partnered in 2022, with Merck evaluating the Quris BioAI machine learning platform and comparing it with traditional in vitro and preclinical animal trials. The collaboration was expanded in September 2023, with Merck utilizing the company’s AI platform to assess the liver toxicity risk of candidate drugs.
Significance of the Adoption
The adoption of the Quris AI platform by Merck KGaA highlights the growing importance of AI in drug development. By integrating the Bio-AI platform into its pipeline, Merck aims to enhance the efficiency and accuracy of preclinical testing, potentially reducing development time and costs while improving the overall success rate of new drug candidates.
Future Prospects
This expanded partnership underscores the potential of AI-driven platforms like Quris AI to revolutionize the drug development process. As more pharmaceutical companies adopt such technologies, the industry is poised to see significant advancements in bringing innovative and effective treatments to market.-Fineline Info & Tech
